Fusen Pharmaceutical Co., Ltd. (HK:1652) has released an update.
Fusen Pharmaceutical Co., Ltd. has announced the successful submission and acceptance of their application to launch ‘Doxazosin Mesylate Extended-Release Tablets’ by the National Medical Products Administration in China. These tablets, targeting the treatment of benign prostatic hyperplasia and hypertension, are expected to provide new options for patients, capitalizing on their proven efficacy, safety, and benefits comparable to existing treatments. The product’s introduction is set to enhance the company’s portfolio in the urology and circulatory system markets.
For further insights into HK:1652 stock, check out TipRanks’ Stock Analysis page.